PUMA BIOTECHNOLOGY INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$10.44
-0.95%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
+6.1%
3 months
+35.8%
6 months
+39.4%
1 year
+91.2%
Year to date
+75.5%
52-week range
$4.73 – $11.26
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$538.9M
P/E
20.2
P/B
3.9
P/S
2.3
Revenue
$231.24M
Net income
$26.72M
Diluted EPS
0.52
Gross margin
74.80%
Net margin
11.60%
Return on equity
20.90%
Total debt
$4.82M
Cash
$36.54M
Free cash flow
$41.16M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $56.5M | $8.19M | 77.90% | 14.50% | $1.62M |
| Mar 31, 2026 | $44.81M | -$3.75M | 76.70% | -8.40% | $15.42M |
| Dec 31, 2025 | $75.45M | $13.44M | 69.30% | 17.80% | $14.46M |
| Sep 30, 2025 | $54.48M | $8.84M | 77.70% | 16.20% | $9.66M |
| Jun 30, 2025 | $52.44M | $5.86M | 76.50% | 11.20% | $14.06M |
| Mar 31, 2025 | $46.01M | $2.97M | 77.10% | 6.50% | $3.55M |
| Dec 31, 2024 | $59.08M | $19.31M | 76.40% | 32.70% | $15.59M |
| Sep 30, 2024 | $80.54M | $20.32M | 63.90% | 25.20% | $11.02M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent PBYI news
All market newsNo ticker-linked stories are in the current archive.